1 completed, 1 withdrawn. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Philip Grant: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Reducing Nucleotide Exposure on Bone Health (ReNew) Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC), Current tenofovir alafenamide (TAF)-containing ART regimen - HIV/AIDS, HIV-1-infection | Phase 2 | Withdrawn | Philip Grant | 2019-08-01 | 2021-03-15 | |
| Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir Rilpivirine/Emtricitabine/Tenofovir - HIV | Phase 2 / Phase 3 | Completed | Philip Grant | 150 | 2014-04-01 | 2021-03-17 |
Acquired Immunodeficiency Syndrome (1) · Bone Diseases, Metabolic (1)
Emtricitabine, Rilpivirine, Tenofovir Drug Combination (1) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (1) · Lamivudine (1) · Rilpivirine (1) · dolutegravir (1)
Rwanda (1) · United States (1)